Study of genetic factors in congenital heart defects
Congenital Heart Disease GEnetic NEtwork Study (CHD GENES)
Children's Hospital Medical Center, Cincinnati · NCT01196182
This study is trying to find out how genetics play a role in congenital heart defects by collecting samples and information from children with these conditions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | N/A to 99 Years |
| Sex | All |
| Sponsor | Children's Hospital Medical Center, Cincinnati (other) |
| Locations | 13 sites (Los Angeles, California and 12 other locations) |
| Trial ID | NCT01196182 on ClinicalTrials.gov |
What this trial studies
The Congenital Heart Disease GEnetic NEtwork Study (CHD GENES) is a multi-center, prospective observational cohort study aimed at understanding the genetic underpinnings of congenital heart defects (CHD). Participants will be recruited from specialized pediatric cardiac centers, where biological specimens will be collected for genetic analysis alongside phenotype data gathered through interviews and medical records. The study utilizes advanced genomic technologies to identify common genetic causes and modifiers of clinical outcomes in CHD, contributing to a biorepository for future research.
Who should consider this trial
Good fit: Ideal candidates for this study include individuals diagnosed with congenital heart defects who can provide informed consent.
Not a fit: Patients with isolated patent foramen ovale or isolated prematurity-associated patent ductus arteriosus may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of congenital heart defects, potentially enhancing patient outcomes.
How similar studies have performed: Other studies focusing on genetic factors in congenital heart defects have shown promise, indicating that this approach is both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: • Signed consent form Exclusion Criteria: * Isolated patent foramen ovale * Isolated prematurity-associated patent ductus arteriosus
Where this trial is running
Los Angeles, California and 12 other locations
- Children's Hospital Los Angeles — Los Angeles, California, United States (RECRUITING)
- Stanford University — Palo Alto, California, United States (COMPLETED)
- University of California, San Francisco — San Francisco, California, United States (COMPLETED)
- Yale University — New Haven, Connecticut, United States (RECRUITING)
- Brigham & Women's Hospital — Boston, Massachusetts, United States (RECRUITING)
- Children's Hospital Boston — Boston, Massachusetts, United States (RECRUITING)
- Cohen Children's Medical Center New York — New Hyde Park, New York, United States (COMPLETED)
- Mount Sinai School of Medicine — New York, New York, United States (RECRUITING)
- Columbia University Medical Center — New York, New York, United States (RECRUITING)
- University of Rochester — Rochester, New York, United States (COMPLETED)
- Children's Hospital Philadelphia — Philadelphia, Pennsylvania, United States (COMPLETED)
- University of Utah — Salt Lake City, Utah, United States (RECRUITING)
- University College London — London, United Kingdom (COMPLETED)
Study contacts
- Principal investigator: Amy Roberts, MD — Childrens Hospital Boston
- Study coordinator: Eileen King, PhD
- Email: B2BProgram@cchmc.org
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Congenital Heart Defects